摘要
目的评价化疗联合自体CIK(cytokine-induced killer)细胞治疗转移性肾癌的临床疗效及安全性。方法 19例转移性肾癌患者接受至少1周期的5-氟尿嘧啶和(或)吉西他滨(5-fluorouracil/gemcit-abine,5-Fu/Gem)化疗,化疗结束后接受4～8次CIK细胞治疗,细胞回输后应用3天d1～d3白细胞介素-2(interleukin-2,IL-2)和胸腺肽α-1。结果 19例患者中1例部分缓解(PR),13例稳定(SD),5例进展(PD),疾病总控制率(CP+PR+SD)为73.68%。评价为PD的5例患者无进展生存期(PFS)为(4.43±2.85)月;其余14例患者PFS未到,中位PFS已达11.64月。结论 CIK细胞联合化疗治疗转移性肾癌疗效确切,疾病控制率得到明显提高,患者带瘤生存时间明显延长。
Objective To evaluate the clinical efficacy and safety of autologous CIK cell adoptive immunotherapy combined with chemotherapy in patients with metastatic renal cell carcinoma（mRCC）.Methods Ninteen mRCC patients were enrolled and received at least one cycle of 5-fluorouracil/gemcitabine regimen chemotherapy,followed by 4-8 times of CIK cell transfusion and 3 doses（d1~d3） of interleukin-2（IL-2） and Thymosin α1.Results Among the 19 cases,PR,SD and PD were 1,13 and 5,respectively.Disease control rate（CR＋PR＋SD） was 73.68%.PFS in 5 patients with PD was 4.43±2.85 months,while PFS in the other 14 cases has reached 11.64 months.Conclusion Our results indicated that autologous CIK cell adoptive immunotherapy combined with chemotherapy has potential benefits and might provide a potent treatment approach for mRCC patients.
出处
《肿瘤防治研究》
CAS
CSCD
北大核心
2012年第6期722-724,共3页
Cancer Research on Prevention and Treatment
基金
国家自然科学基金青年科学基金资助项目(81000914)
河南省科技攻关计划重大项目(201001012
2011010011)
关键词
细胞因子诱导的杀伤细胞
免疫治疗
化疗
转移性肾癌
Cytokine-induced killer cells
Immunotherapy
Chemotherapy
Metastatic renal cell carcinoma
